{"id":"renin-angiotensin-raas-alone","safety":{"commonSideEffects":[{"rate":"10-20","effect":"Cough (ACE inhibitors)"},{"rate":"2-5","effect":"Hyperkalemia"},{"rate":"5-10","effect":"Dizziness"},{"rate":"3-8","effect":"Fatigue"},{"rate":"0.1-0.5","effect":"Angioedema"}]},"_chembl":{"chemblId":"CHEMBL2391146","moleculeType":"Protein","molecularWeight":"956.07"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The renin-angiotensin-aldosterone system (RAAS) is a hormonal cascade that regulates blood pressure and fluid balance. RAAS inhibitors (including ACE inhibitors, ARBs, direct renin inhibitors, and aldosterone antagonists) interrupt this pathway at various points, reducing vasoconstriction and aldosterone-mediated sodium retention, thereby lowering blood pressure and reducing proteinuria. These agents are used alone or in combination for cardiovascular and renal protection.","oneSentence":"RAAS inhibitors block the renin-angiotensin-aldosterone system to reduce blood pressure and protect organs from hypertension-related damage.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:04:41.785Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Hypertension"},{"name":"Heart failure"},{"name":"Chronic kidney disease"},{"name":"Post-myocardial infarction"},{"name":"Diabetic nephropathy"}]},"trialDetails":[{"nctId":"NCT05593770","phase":"PHASE2, PHASE3","title":"International Sites: Novel Experimental COVID-19 Therapies Affecting Host Response","status":"TERMINATED","sponsor":"NEAT ID Foundation","startDate":"2022-10-27","conditions":"COVID-19, SARS-CoV2 Infection, Coronavirus Infection","enrollment":28},{"nctId":"NCT04924660","phase":"PHASE2, PHASE3","title":"Novel Experimental COVID-19 Therapies Affecting Host Response","status":"COMPLETED","sponsor":"Sean Collins","startDate":"2021-07-15","conditions":"COVID-19, SARS-CoV-2 Infection, Coronavirus Infection","enrollment":1060},{"nctId":"NCT05169411","phase":"","title":"Preserving Kidney Function in Children With Chronic Kidney Disease","status":"COMPLETED","sponsor":"Children's Hospital of Philadelphia","startDate":"2023-09-22","conditions":"Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3, Pediatric Kidney Disease","enrollment":20240},{"nctId":"NCT06515678","phase":"","title":"Impact of Antihypertensive Therapy on Recurrence Risk of Ovarian Cancer for Bevacizumab-associated Hypertension","status":"ACTIVE_NOT_RECRUITING","sponsor":"Groupe Hospitalier Pitie-Salpetriere","startDate":"2024-05-20","conditions":"Ovarian Cancer, Antiangiogenic-Associated Hypertension, Adjuvant Bevacizumab","enrollment":9464},{"nctId":"NCT03502031","phase":"PHASE4","title":"Safety and Efficacy of Two Year of RAAS Alone or in Combination With Spironolactone Therapy","status":"UNKNOWN","sponsor":"James A. Tumlin, MD","startDate":"2018-10-01","conditions":"Renal Insufficiency, Chronic, Diabetic Nephropathy Type 2","enrollment":72},{"nctId":"NCT01716819","phase":"NA","title":"Role of the Renin Angiotensin Aldosterone System in the Mechanisms of Transition to Heart Failure in Abdominal Obesity","status":"COMPLETED","sponsor":"Central Hospital, Nancy, France","startDate":"2012-11","conditions":"Obesity, Abdominal","enrollment":101}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":216,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Lispril, Enalapril, Perindopril, Losarta, Valsar etc.,"],"phase":"marketed","status":"active","brandName":"Renin-Angiotensin (RAAS) alone","genericName":"Renin-Angiotensin (RAAS) alone","companyName":"James A. Tumlin, MD","companyId":"james-a-tumlin-md","modality":"Small molecule","firstApprovalDate":"","aiSummary":"RAAS inhibitors block the renin-angiotensin-aldosterone system to reduce blood pressure and protect organs from hypertension-related damage. Used for Hypertension, Heart failure, Chronic kidney disease.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}